536 related articles for article (PubMed ID: 11359810)
1. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
[TBL] [Abstract][Full Text] [Related]
2. Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.
Inui T; Nakagawa R; Ohkura S; Habu Y; Koike Y; Motoki K; Kuranaga N; Fukasawa M; Shinomiya N; Seki S
J Immunol; 2002 Dec; 169(11):6127-32. PubMed ID: 12444115
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.
Habu Y; Uchida T; Inui T; Nakashima H; Fukasawa M; Seki S
Immunology; 2004 Sep; 113(1):35-43. PubMed ID: 15312134
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
[TBL] [Abstract][Full Text] [Related]
5. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.
Nakagawa R; Inui T; Nagafune I; Tazunoki Y; Motoki K; Yamauchi A; Hirashima M; Habu Y; Nakashima H; Seki S
J Immunol; 2004 Jun; 172(11):6550-7. PubMed ID: 15153469
[TBL] [Abstract][Full Text] [Related]
6. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells.
Biburger M; Tiegs G
J Immunol; 2005 Aug; 175(3):1540-50. PubMed ID: 16034092
[TBL] [Abstract][Full Text] [Related]
7. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice.
Inui T; Nakashima H; Habu Y; Nakagawa R; Fukasawa M; Kinoshita M; Shinomiya N; Seki S
J Hepatol; 2005 Oct; 43(4):670-8. PubMed ID: 15922476
[TBL] [Abstract][Full Text] [Related]
9. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.
Smyth MJ; Crowe NY; Pellicci DG; Kyparissoudis K; Kelly JM; Takeda K; Yagita H; Godfrey DI
Blood; 2002 Feb; 99(4):1259-66. PubMed ID: 11830474
[TBL] [Abstract][Full Text] [Related]
10. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.
Nishihori Y; Kato K; Tanaka M; Okamoto T; Hagiwara S; Araki N; Kogawa K; Kuribayashi K; Nakamura K; Niitsu Y
Cancer Biol Ther; 2009 Sep; 8(18):1763-70. PubMed ID: 19901518
[TBL] [Abstract][Full Text] [Related]
12. Participation of NK1.1+ T cells in the rejection of lpr alphabetaT cells when bone marrow cells of lpr mice are transplanted into B6 mice.
Tsukahara A; Kawamura H; Iiai T; Moroda T; Suzuki S; Tada T; Minagawa M; Musha N; Hatakeyama K; Abo T
Microbiol Immunol; 1998; 42(6):447-56. PubMed ID: 9688079
[TBL] [Abstract][Full Text] [Related]
13. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
14. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
15. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice.
Yang JQ; Saxena V; Xu H; Van Kaer L; Wang CR; Singh RR
J Immunol; 2003 Oct; 171(8):4439-46. PubMed ID: 14530371
[TBL] [Abstract][Full Text] [Related]
16. IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners.
Sun R; Tian Z; Kulkarni S; Gao B
J Immunol; 2004 May; 172(9):5648-55. PubMed ID: 15100309
[TBL] [Abstract][Full Text] [Related]
17. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
[TBL] [Abstract][Full Text] [Related]
18. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation.
Trobonjaca Z; Kröger A; Stober D; Leithäuser F; Möller P; Hauser H; Schirmbeck R; Reimann J
J Immunol; 2002 Apr; 168(8):3763-70. PubMed ID: 11937527
[TBL] [Abstract][Full Text] [Related]
19. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.
Osman Y; Kawamura T; Naito T; Takeda K; Van Kaer L; Okumura K; Abo T
Eur J Immunol; 2000 Jul; 30(7):1919-28. PubMed ID: 10940881
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
Baxevanis CN; Gritzapis AD; Papamichail M
J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
